Business Wire

SK Capital Completes Strategic Investment in Ecopol

14.9.2023 07:30:00 EEST | Business Wire | Press release

Share

Ecopol S.p.A. (“Ecopol” or the “Company”), a leading developer and producer of innovative biodegradable films and delivery systems, announced today the completion of a strategic investment from affiliates of SK Capital Partners, LP (“SK Capital”), a leading private investment firm focused on the specialty materials, ingredients, and life sciences sectors. SK Capital has acquired a majority interest in the Company with Mauro Carbone, Ecopol’s CEO and controlling shareholder, retaining a significant stake and remaining as both the CEO and largest individual shareholder. It is also announced the formation of a new Board of Directors, which includes industry leaders with extensive experience across sustainable materials and consumer packaged goods (“CPG”) markets in Ecopol’s value chains, including Jan-Dirk Auris, E. Craig Mitchell, Daniele Ferrari and Dave Mezzanotte.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913054522/en/

“Ecopol is pleased to begin our partnership with SK Capital and to be working with a diverse team of high-impact industry executives who have joined our Board of Directors,” said Mauro Carbone, Ecopol CEO. “I am excited for the next chapter of our journey as we work together to accelerate Ecopol’s rapid growth and continue to make strategic investments to provide even greater value for our global customer base and bring more sustainable solutions to both existing and new markets. We are grateful to Roberto Quagliuolo, Luca Bucelli and Laurent Labatut for their contributions as former Board Directors and look forward to Tikehau Capital’s continued support as an ongoing minority shareholder.”

“In partnership with Mauro, we have assembled a world-class Board of Directors who will be highly impactful in helping Ecopol execute its strategic priorities and achieve its vision to become the global leader in highly innovative and sustainable delivery systems,” added Stephen D’Incelli, Managing Director at SK Capital. “We look forward as a Board to supporting Mauro and his leadership team in driving Ecopol’s next phase of transformational growth.”

In connection with the closing, SK Capital and Mauro have appointed the following Board Directors:

Jan-Dirk Auris spent over 35 years at Henkel AG & Co. KGaA (“Henkel”), where he served in a variety of senior executive roles and as a member of the Henkel Management Board. He most recently led Henkel’s Adhesives Technologies business unit, where he had extensive experience serving leading global CPG companies. Mr. Auris played a leading role in implementing a new performance management playbook across Henkel and driving innovation and sustainability initiatives.

E. Craig Mitchell has over 35 years of experience in the specialty materials industry and currently serves as President, Flavors and Extracts Group at Sensient Technologies Corporation. He previously served in critical roles at global leaders in Ecopol’s supply chain, including President and COO of Sekisui Specialty Chemicals America, LLC, a manufacturer of polyvinyl alcohol, as well as VP of Sales, Americas of Celanese Corporation, a producer of vinyl acetate monomer.

Daniele Ferrari will serve as Board Chairman. Mr. Ferrari, who is based full-time in Italy, has over 35 years of experience in the specialty materials industry, most recently as the CEO of Versalis S.p.A., the largest chemical company in Italy, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of renewable chemistry. Mr. Ferrari has served as a Senior Director at SK Capital and brings significant sustainability leadership in prior roles as President of the European Chemical Industry Council (“CEFIC”), President of Plastics Europe, and as a board member of the Alliance to End Plastics Waste.

Dave Mezzanotte has over 40 years of experience in the specialty materials and packaging industries and has served as a Senior Director at SK Capital since 2018. He previously was Chairman and CEO of Coveris, a global manufacturer of flexible consumer packaging, and CEO of CHEP, a global logistics services provider for CPGs.

The Board of Directors also includes Mauro Carbone, Ecopol CEO and significant minority investor; Stephen d’Incelli, Deal Lead and Managing Director at SK Capital; and Josh Lieberman, Principal at SK Capital.

Latham & Watkins LLP served as legal counsel to SK Capital. Lead arrangers and bookrunners Crédit Agricole Italia S.p.A. and Intesa Sanpaolo S.p.A provided committed financing in support of the transaction. Legance and Alpeggiani Studio Legale Associato served as legal counsel and STS Deloitte served as tax advisor to Ecopol. UBS served as financial advisor.

About Ecopol

Ecopol is a leading global producer of water-soluble and biodegradable films. The Company’s innovative delivery systems for unit-dose applications allow the world’s leading brands to significantly reduce CO2 emissions and the usage of water and virgin plastic throughout their supply chains. Headquartered in Chiesina Uzzanese, Tuscany, Ecopol operates production campuses in Italy and the United States, providing the highest levels of service, technical support and innovation partnership to its worldwide customer base. For more information, please visit www.ecopol.com.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients and life sciences sectors. The firm seeks to build resilient, sustainable and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $17 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The firm currently has approximately $7.8 billion in assets under management. For more information, please visit www.skcapitalpartners.com.

About Tikehau Capital

Tikehau Capital is a global alternative asset management group with €41.1 billion of assets under management (as of 30 June 2023). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Leveraging its strong equity base (€3.1 billion of shareholders’ equity as of 30 June 2023), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 742 employees (as of 30 June 2023) across its 15 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit www.tikehaucapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye